Publications

Editorial: Reading the cholate—A new gateway to portal hypertension and oesophageal varices: Authors’ reply

Tarek Hassanein, Andrew P. Keaveny, Parvez Mantry, Alastair D. Smith, Michael P. McRae, John Kittelson, Steve Helmke, Gregory T. Everson, for the SHUNT-V Investigators | Aliment Pharmacol Ther 2024

Hepatic improvement within 27 days of avenciguat treatment in Child-Pugh A cirrhosis detected by an oral cholate challenge test

Eric J. Lawitz, Judith Ertle, Corinna Schoelch, Isabella Gashaw, Steve M. Helmke, Gregory T Everson | Liver Transplantation 2024 Jun 12

Liver Function and Portal-Systemic Shunting Quantified by the Oral Cholate Challenge Test and Risk for Large Esophageal Varices

Tarek Hassanein, Andrew P. Keaveny, Parvez Mantry, Alastair D. Smith, Michael P. McRae, John Kittelson, Steve Helmke, Gregory T. Everson for the SHUNT-V Investigators | Aliment Pharmacol Ther 2024 May 22

Hepatic Dysfunction Quantified by HepQuant DuO Outperforms Child-Pugh Classification in Predicting the Pharmacokinetics of Ampreloxetine

Jitendra Kanodia, Hugh Giovinazzo, Wayne Yates, David L. Bourdet, Steve M. Helmke, and Gregory T. Everson | Clin Pharmacol Ther 2024 Apr 23

Within Individual Reproducibility of a Dual Sample Oral Cholate Challenge Test (DuO) and Simplified Versions of the HepQuant SHUNT Test

Michael P. McRae, John Kittelson, Steve M. Helmke, and Gregory T. Everson | Clin Translational Sci 2024

Dynamic elevation of aromatic amino acids in Hepatitis C Virus induced cirrhosis after a standard meal

Hill KL, Haddad JA, Ali RO, Zhang GY, Quinn GM, Townsend E, Everson GT, Helmke SM, Bagheri M, Schoenfeld M, Yang S, Koh C, Levy EB, Kleiner DE, Sacks DB, Etzion O, Heller T. | Clinical and Translational Gastroenterology 2024;15:e00666

Portal-systemic shunting in patients with fibrosis or cirrhosis due to chronic hepatitis C: the minimal model for measuring cholate clearances and shunt

Everson GT, Martucci MA, Shiffman ML, Sterling RK, Morgan TR, Hoefs JC, The HALT-C Trial Group (2007) | Aliment Pharmacol Ther, 26(3):401-10

Safety and pharmacokinetics of BI 685509, a soluble guanylyl cyclase activator, in patients with cirrhosis: A randomized Phase Ib study

Eric J. Lawitz, Thomas Reiberger, Jörn M. Schattenberg, Corinna Schoelch, Harvey O. Coxson, Diane Wong, Judith Ertle | Hepatology Communications. 2023 Mar 0;7:e0276

Compartmental model describing the physiological basis for the HepQuant SHUNT test

Michael P. McRae, Steve M. Helmke, James R. Burton Jr., and Gregory T. Everson | Transl Res. Volume 252, P53-63, February 2023

The within-individual reproducibility of the disease severity index from the HepQuant SHUNT test of liver function and physiology

Burton, James R. et al. | Transl Res. 2021 Jul;233:5-15